← 返回

识别胰腺癌中的免疫细胞浸润景观以辅助免疫治疗

英文原题:Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.

查看英文原题

Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.

PubMed 2021/08/04(内容时间) Future Oncol Q2 · IF 3.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

恶性肿瘤的免疫环境,包括浸润免疫细胞状态,可能对患者预后至关重要。近期研究表明,胰腺癌(PC)中的免疫细胞浸润(ICI)与免疫治疗反应及患者预后高度相关。因此,我们旨在构建一个能够准确预测患者预后和免疫治疗疗效的ICI评分。

使用两种计算算法(CIBERSORT和ESTIMATE),从公开可用的癌症基因组图谱(TCGA)胰腺导管腺癌和GSE57495基因表达数据集中评估PC患者的ICI状态。使用聚类算法定义ICI和转录组亚组,并进行生存分析。使用主成分分析计算新的ICI评分,并进行基因集富集分析以识别所定义聚类背后的通路。在TCGA队列中进一步探讨肿瘤突变负荷(TMB),并使用生存分析评估ICI和TMB评分预测总生存期的能力。此外,还研究了不同ICI评分组中的常见驱动基因突变及其差异表达。

使用所设计的算法生成了240例患者的ICI景观,揭示了三个ICI聚类和三个基因聚类,使用这些聚类改善了总生存期预测(分别为p = 0.019和p < 0.001)。关键免疫检查点基因在这些亚型之间存在差异表达;RIG-I-LIKE和NOD-LIKE受体信号通路在低ICI评分样本中富集(p < 0.05)。我们还发现,TMB评分可以预测生存结局,而ICI评分也可以独立于TMB预测预后。值得注意的是,ICI评分可以有效预测对免疫治疗的应答。KRAS、TP53、CDKN2A、SMAD4和TTN仍然是PC中最常见的突变基因;此外,KRAS和TP53突变率在两个ICI评分组之间显著不同。

我们开发了一种新的ICI评分,可以独立预测PC患者对免疫治疗的应答和生存。在更大的队列中评估ICI景观可以阐明这些浸润细胞、肿瘤微环境和对免疫治疗应答之间的相互作用。通俗摘要 胰腺癌(PC)是一种致死性恶性肿瘤,死亡率较高。目前,免疫治疗越来越受到临床研究人员的关注,并被认为是一种新型有效的治疗方法。然而,在临床实践中,免疫治疗并未在所有患者中表现出一致的治疗应答。因此,基于免疫细胞浸润识别晚期PC患者中对免疫治疗敏感的亚组很重要。在本研究中,我们下载并处理了来自TCGA-PAAD和GEO数据库的转录组数据,并使用CIBERSORT和ESTIMATE算法揭示了胰腺癌的免疫细胞浸润景观。根据共识聚类结果,我们确定了三个ICI和基因簇,用于指导未来临床治疗中免疫亚型的识别。最后,我们为每个受试者计算了ICI评分,以描述其肿瘤免疫景观,并对所有患者进行了风险分组和多组学分析。总之,ICI评分和聚类未来可用于帮助临床医生识别最有可能对免疫治疗产生应答的患者。

展开英文摘要原文

Background: A malignant tumor's immune environment, including infiltrating immune cell status, can be critical to patient outcomes. Recent studies have shown that immune cell infiltration (ICI) in pancreatic cancer (PC) is highly correlated with the response to immunotherapy and patient prognosis.

Therefore, we aimed to create an ICI score that accurately predicts patient outcomes and immunotherapeutic efficacy. Methods: The ICI statuses of patients with PC were estimated from the publicly available The Cancer Genome Atlas (TCGA) pancreatic ductal adenocarcinoma and GSE57495 gene expression datasets using two computational algorithms (CIBERSORT and ESTIMATE).

ICI and transcriptome subsets were defined using a clustering algorithm, and survival analysis was also performed. Principal component analysis was used to calculate the novel ICI score, and gene set enrichment analysis was performed to identify the pathways underlying the defined clusters. The tumor mutational burden (TMB) was further explored in TCGA cohort, and survival analysis was used to assess the capability of the ICI and TMB scores to predict overall survival.

Additionally, common driver gene mutations and their differential expression in the different ICI score group were investigated. Results: The ICI landscapes of 240 patients were generated using the devised algorithm, revealing three ICI and three gene clusters whose use improved the prediction of overall survival (p = 0. 019 and p < 0. 001, respectively). Crucial immune checkpoint genes were differentially expressed among these subtypes; the RIG-I-LIKE and NOD-LIKE receptor signaling pathways were enriched in samples with low ICI scores (p < 0. 05).

We also found that the TMB scores could predict survival outcomes, whereas the ICI scores also could predict prognoses independent of TMB.

Notably, ICI scores could effectively predict responses to immunotherapy. KRAS , TP53 , CDKN2A , SMAD4 and TTN remained the most commonly mutated genes in PC; moreover, KRAS and TP53 mutation rates were significantly different between the two ICI score groups. Conclusions: We developed a novel ICI score that could independently predict the response to immunotherapy and survival of patients with PC.

Evaluation of the ICI landscape in a larger cohort could clarify the interactions between these infiltrating cells, the tumor microenvironment and response to immunotherapy. Lay abstract Pancreatic cancer (PC) is a lethal malignancy with a higher mortality rate. Currently, immunotherapy is increasingly interesting to clinical researchers and considered a novel and efficient treatment.

However, in clinical practice, immunotherapy has not demonstrated consistent therapeutic responses across all patients.

Thus, to identify the immunotherapy-sensitive subgroup of advanced PC patients is important based on immune cell infiltration. In this study, we downloaded and processed transcriptomic data from TCGA-PAAD and GEO databases and used CIBERSORT and ESTIMATE algorithms to reveal the immune cell infiltration landscape of pancreatic cancer. According to consensus clustering results, we identified three ICI and gene clusters for guiding the identification of immune-subtype in future clinical treatments.

Finally, we calculated an ICI score for each subject to describe their tumor immune landscape and performed the risk grouping for all patients and multiomics analysis. In sum, the ICI score and clusters could be used in the future to assist clinicians in identifying patients with the greatest chance of responding to immunotherapy.

论文信息

作者
Wang Z、Zou W、Wang F、Zhang G、Chen K、Hu M、Liu R
单位
Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital, Institute of Hepatobiliary Surgery of Chinese PLA, &amp; Key Laboratory of Digital Hepetobiliary Surgery, PLA, Beijing, China.China
期刊
Future oncology (London, England)2021 Nov
原文标识
PubMed 34346253 · DOI 10.2217/fon-2021-0495